MedTrace Logo

Homecoming Line: Telephone Support for Veterans

NCT02655991 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 358

Last updated 2016-01-14

No results posted yet for this study

Summary

This study will determine whether telephone support improves clinical outcomes of veterans who begin outpatient treatment for posttraumatic stress disorder. Participants will be randomly assigned to receive either usual care or usual care supplemented by biweekly monitoring and support by telephone during the first 3 months of treatment. Patients in both conditions will be compared on PTSD symptoms, engagement in treatment, violence and drinking at 4 months and 12 months after entering treatment.

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

BEHAVIORAL

Telephone Case Monitoring

Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.

BEHAVIORAL

Treatment as Usual

Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).

Sponsors & Collaborators

  • Durham VA Medical Center

    collaborator FED

  • VA Puget Sound Health Care System

    collaborator FED

  • VA Palo Alto Health Care System

    lead FED

Principal Investigators

  • Craig S. Rosen, Ph.D. · VA Palo Alto Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655991 on ClinicalTrials.gov